[Prevention of pancreatic fistula after pancreatoduodenectomy]

What Was Tested

Researchers studied Somatostatin in the context of pancreatitis (after the acute phase) in this randomized controlled trial publication.

To assess the effect of drug prophylaxis on the development of pancreatic fistula the researchers used logistic regression models with the inclusion of the drug use factor as an independent variable.

Who Took Part

The study group was 2020 patients.

In period from December 2018 till March 2020 78 patients underwent pancreatoduodenectomy for pancreatobilliary tumors in department of abdominal surgery of National Medical Research Center of Surgery named after A.V.

In both groups patients were randomized to main and control subgroups.

How the Study Was Run

The design is described as randomized.

Because people in this Somatostatin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

In main subgroup of high risk group patients combination of somatostatin analogues and glucocorticoids was used, while in control subgroup patients received only somatostatin analogue.

What Was Measured

Topics PubMed links to this paper include Biliary Tract Neoplasms, Gastrointestinal Agents, Glucocorticoids, Pancreas, Pancreatic Fistula, Pancreatic Neoplasms and Pancreaticoduodenectomy.

Author keywords: pancreatoduodenectomy and somatostatin analogue.

What This Means in Plain Language

The paper is a randomized study of Somatostatin in 2020 patients in people with pancreatitis (after the acute phase).

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2020 (Khirurgiia), a journal based in Russia (Federation).

More context: the Somatostatin compound page, Pancreatitis (after the acute phase) research.